Rheumatol Int DOI 10.1007/s00296-013-2926-6
Original Article
Circulating anti‑cyclic citrullinated peptide antibody in patients with rheumatoid arthritis and chronic obstructive pulmonary disease Deng‑Ho Yang · Chuan‑Chou Tu · Shou‑Cheng Wang · Cheng‑Chung Wei · Ya‑Wen Cheng
Received: 25 October 2013 / Accepted: 14 December 2013 © Springer-Verlag Berlin Heidelberg 2013
Abstract Anti-cyclic citrullinated peptide (anti-CCP) antibody is highly specific for diagnosing rheumatoid arthritis (RA). Cigarette smoking is a lifestyle and environmental factor associated with anti-CCP production and is strongly associated with chronic obstructive pulmonary disease (COPD). This study assessed levels of anti-CCP antibodies and rheumatoid factor (RF) among patients with RA and COPD. The study sample comprised 63 patients with RA and 70 patients with COPD, all of whom underwent assessment of anti-CCP antibody and RF levels. Testing revealed that 54.2 % of RA patients and 0 % of COPD patients were positive for anti-CCP antibodies. Additionally, 82.5 % of RA patients and 42 % of COPD patients were positive for RF. Among RA patients, levels of antiCCP antibodies were higher among smokers than among D.-H. Yang · C.-C. Wei · Y.-W. Cheng (*) Institute of Medicine, Chung Shan Medical University, No. 110, Sec. 1, Jianguo N. Rd., Taichung 40201, Taiwan e-mail: [email protected] D.-H. Yang Division of Rheumatology/Immunology/Allergy, Department of Internal Medicine, Taichung Armed-Forces General Hospital, Taichung, Taiwan C.-C. Tu · S.-C. Wang Division of Pulmonary Medicine and Respiratory Therapy, Department of Internal Medicine, Taichung Armed-Forces General Hospital, Taichung, Taiwan C.-C. Wei Division of Rheumatology/Immunology/Allergy, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan Y.-W. Cheng Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University, Taipei, Taiwan
nonsmokers (242.7 ± 128.3 vs. 68.1 ± 112.1, P
Original Article
Circulating anti‑cyclic citrullinated peptide antibody in patients with rheumatoid arthritis and chronic obstructive pulmonary disease Deng‑Ho Yang · Chuan‑Chou Tu · Shou‑Cheng Wang · Cheng‑Chung Wei · Ya‑Wen Cheng
Received: 25 October 2013 / Accepted: 14 December 2013 © Springer-Verlag Berlin Heidelberg 2013
Abstract Anti-cyclic citrullinated peptide (anti-CCP) antibody is highly specific for diagnosing rheumatoid arthritis (RA). Cigarette smoking is a lifestyle and environmental factor associated with anti-CCP production and is strongly associated with chronic obstructive pulmonary disease (COPD). This study assessed levels of anti-CCP antibodies and rheumatoid factor (RF) among patients with RA and COPD. The study sample comprised 63 patients with RA and 70 patients with COPD, all of whom underwent assessment of anti-CCP antibody and RF levels. Testing revealed that 54.2 % of RA patients and 0 % of COPD patients were positive for anti-CCP antibodies. Additionally, 82.5 % of RA patients and 42 % of COPD patients were positive for RF. Among RA patients, levels of antiCCP antibodies were higher among smokers than among D.-H. Yang · C.-C. Wei · Y.-W. Cheng (*) Institute of Medicine, Chung Shan Medical University, No. 110, Sec. 1, Jianguo N. Rd., Taichung 40201, Taiwan e-mail: [email protected] D.-H. Yang Division of Rheumatology/Immunology/Allergy, Department of Internal Medicine, Taichung Armed-Forces General Hospital, Taichung, Taiwan C.-C. Tu · S.-C. Wang Division of Pulmonary Medicine and Respiratory Therapy, Department of Internal Medicine, Taichung Armed-Forces General Hospital, Taichung, Taiwan C.-C. Wei Division of Rheumatology/Immunology/Allergy, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan Y.-W. Cheng Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University, Taipei, Taiwan
nonsmokers (242.7 ± 128.3 vs. 68.1 ± 112.1, P
